Some people have the benefits of omega 3 … Confirmation from a new clinical paper

There is an ongoing battle in the medical community over the cardiovascular protective effect of omega-3. This time, the use of omega 3 was supported because the effect of high dose / refined ingredients was seen in a study on patients with a low ratio of unsaturated fatty acids in the body.

At the American Heart Association Annual Meeting (AHA 2022), a new clinical trial examining the cardiovascular protective effects of omega-3 was announced on the 7th.

The debate about whether omega 3 (the main ingredient EPA + DHA) has a cardiovascular protective effect has been repeated for 20 years, starting in 2022.

According to a recent study, the effect was demonstrated in the REDUCE-IT clinical trial using the omega-3 tablet ingredient EPA at a high dose of 4g per day, but the reliability was compromised by the possibility of clinical design error.

The RESPECT-EPA clinical trial, published this time, looked at the prevention of cardiovascular events by giving 1800 mg of highly pure EPA per day to patients with chronic coronary artery disease (CAD) with an EPA to arachidonic acid (AA) ratio of less than 0.4.

Subjects were limited to those who received statins for at least 1 month prior to the clinical trial, and the age range varied from 20 to 79 years.

The endpoints of the study were cardiovascular death, fatal myocardial infarction, fatal cerebral infarction, unstable angina, and clinically identified coronary complications. Secondary endpoints included multiple events of CAD, multiple events of stroke and death.

A total of 1225 subjects were assigned to the EPA group and 1235 subjects were assigned to the control group. A total of 1314 patients were enrolled with high EPA/AA ratios, with a value of 0.577. The group with the low EPA/AA ratio had a value of 0.243/0.235.

RESULTS: The primary outcome in the RCT was 112 in the EPA group and 155 in the control group (HR 0.79).

The incidence of coronary events occurred in 81 patients in the EPA group and 120 patients (HR 0.73) in the control group For all other causes of death, the HR was 0.682 and cardiovascular deaths 0.888, reducing the risk in the EPA treated group.

However, the researchers reported that the incidence of new atrial fibrillation was significantly higher in the EPA-treated group than in the control group.

The researchers concluded, “A low EPA/arachidonic acid ratio of less than 0.4 among patients with chronic CAD indicates a predictive benefit of EPA.”

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.